跳至主要内容
临床试验/2024-517763-22-00
2024-517763-22-00招募中4 期

Midazolam and mORPHine to alleviate symptoms at the End of life in patients on acUte geriatric wardS (MORPHEUS study)

UZ Leuven2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2025年1月20日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
UZ Leuven
入组人数
300
试验地点
2
主要终点
Morphine and midazolam doses, time of administration and route of administration

研究概览

简要总结

  1. To characterize the relationship between morphine dosing and the time to symptom control (discomfort/pain and dyspnea) in geriatric patients during their last days of life.
  2. To characterize the relationship between midazolam dosing and the time to symptom control (discomfort/pain, dyspnea and agitation) in geriatric patients during their last days of life.
  3. To characterize the relationship between morphine dosage and the occurrence of adverse drug reactions in geriatric patients during their last days of life.
  4. To characterize the relationship between midazolam dosage and the occurrence of adverse drug reactions in geriatric patients during their last days of life.

入排标准

年龄范围
65 years 至 65+ years(65+ Years)
接受健康志愿者

入选标准

  • Hospitalization on the acute geriatric ward
  • Patient expected to die in the following hours or days

排除标准

  • Expected discharge from the hospital before death

结局指标

主要结局

Morphine and midazolam doses, time of administration and route of administration

Morphine and midazolam doses, time of administration and route of administration

Symptom control: discomfort scale, agitation/sedation scale and dyspnea scale

Symptom control: discomfort scale, agitation/sedation scale and dyspnea scale

Adverse reactions: : nausea, vomiting, hallucinations, constipation, myoclonus, pruritus, hiccups, respiratory rate and other adverse reactions occurring that are related to the Morphine and Midazolam injection according to the nurse or doctor.

Adverse reactions: : nausea, vomiting, hallucinations, constipation, myoclonus, pruritus, hiccups, respiratory rate and other adverse reactions occurring that are related to the Morphine and Midazolam injection according to the nurse or doctor.

次要结局

  • Morphine, morphine-3-glucuronide and morphine-6-glucuronide plasma concentrations
  • Midazolam and alpha-hydroxy-midazolam glucuronide plasma concentrations
  • Blood creatinine, urea, albumin, bilirubin, GGT, ALT, sodium, CRP and urinary creatinine concentrations

研究者

发起方
UZ Leuven
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Tim Biesbrouck

Scientific

UZ Leuven

研究点 (2)

Loading locations...

相似试验